Invex Therapeutics Ltd Sustainability Reports
Invex Therapeutics Ltd is a biopharmaceutical company engaged in the research and development of efficacious treatments for neurological conditions. The company primarily focuses on repurposing and reformulating the approved drug Exenatide to treat diseases derived from or involving raised intracranial pressure.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
FIGI: BBG00PD615Z5
6 reports from 2020 to 2025
